Search clinical trials for: B-Cell Immunotherapy

Total 5408 results

National Cancer Institute (NCI)

Not yet recruiting

Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Chronic Lymphocytic Leukemia (CLL)

Leukemia, Lymphocytic, Chronic, B-Cell | B-Cell Chronic Lymphocytic Leukemia | B-Lymphocytic Leukemia, Chronic

United States
British Columbia Cancer Agency

Not yet recruiting

CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies

B-cell Lymphoma | Non-Hodgkin's Lymphoma | Mantle Cell Lymphoma | Diffuse Large B Cell Lymphoma | B-Cell Leukemia | B-cell Acute Lymphoblastic Leukemia | Primary Mediastinal Large B-cell Lymphoma (PMBCL) | High-grade B-cell Lymphoma

Canada
Fred Hutchinson Cancer Center
Faron Pharmaceuticals Ltd

Not yet recruiting

Interferon-Beta-1a (FP-1201) to Prevent Toxicities After CD19-Directed CAR T-Cell Therapy

Recurrent Mantle Cell Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent B Acute Lymphoblastic Leukemia | Refractory B Acute Lymphoblastic Leukemia | Refractory Mantle Cell Lymphoma

United States
National Cancer Institute (NCI)

Recruiting

Trial of Anti-CD19 and Anti-CD20 Bicistronic Chimeric Antigen Receptor T Cells for Treating B-Cell Malignancies

Lymphoma, B-Cell | Chronic Lymphocytic Leukemia | B-Cell Chronic Lymphocytic Leukemia

United States
National Cancer Institute (NCI)

Recruiting

CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies

Lymphoma, Non-Hodgkin | Acute Lymphoblastic Leukemia | Acute Lymphocytic Leukemia | Acute Lymphoid Leukemia | B-Cell Leukemia | Leukemia, Lymphocytic, B Cell | B-Cell Lymphoma | B-All | B-NHL | B-Non Hodgkin Lymphoma | B-precursor ALL

United States
Mustang Bio
National Cancer Institute (NCI)

Recruiting

Study to Assess Safety, Tolerability and Efficacy of MB-106 in Patients With Relapsed or Refractory B-Cell NHL or CLL

Mantle Cell Lymphoma Recurrent | Mantle Cell Lymphoma Refractory | Small Lymphocytic Lymphoma, Relapsed | Waldenstrom's Macroglobulinemia Recurrent | Follicular B-cell Non-Hodgkin's Lymphoma | B-cell Lymphoma Refractory | Waldenstrom's Macroglobulinemia Refractory | Chronic Lymphoid Leukemia in Relapse

United States
Belarusian Research Center for Pediatric Oncology...

Recruiting

Pilot CAR-T Cells Therapy for Children/Young Adults With CD19+ R/R Leukemia/Lymphoma

B-cell Acute Lymphoblastic Leukemia | Lymphoblastic B-Cell Lymphoma

Belarus
Fred Hutchinson Cancer Center
Swedish Orphan Biovitrum

Recruiting

Anakinra for the Prevention of Cytokine Release Syndrome and Neurotoxicity in Patients With B-Cell Non-Hodgkin Lymphoma Receiving CD19-Targeted CAR-T Cell Therapy

B-Cell Non-Hodgkin Lymphoma

United States
University Hospital, Limoges

Recruiting

Exosomes and Immunotherapy in Non-Hodgkin B-cell Lymphomas (ExoReBLy)

Lymphoma, B-cell, Aggressive Non-Hodgkin (B-NHL)

France
National Cancer Institute (NCI)

Recruiting

CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies

Lymphoma, Non-Hodgkin | Acute Lymphoblastic Leukemia | Acute Lymphocytic Leukemia | Acute Lymphoid Leukemia | B-Cell Leukemia | Leukemia, Lymphocytic, B Cell | B-Cell Lymphoma | B-All | B-NHL | B-Non Hodgkin Lymphoma

United States
University College, London

Recruiting

Immunotherapy for High Risk/Relapsed CD19+ Acute Lymphoblastic Leukaemia, B-cell Non-Hodgkin's Lymphoma (B-NHL) and Chronic Lymphocytic Leukaemia (CLL)/ Small Lymphocytic Lymphoma (SLL) Using CAR T-cells to Target CD19 (ALLCAR19)

Leukemia, Lymphoblastic, Acute, Lymphoma

United Kingdom
Fred Hutchinson Cancer Center
Mustang Bio

Active, not recruiting

A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas

Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent Small Lymphocytic Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Refractory Chronic Lymphocytic... and other conditions

United States
Fred Hutchinson Cancer Center
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

Terminated

huJCAR014 CAR-T Cells in Treating Adult Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia

Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent Adult Acute Lymphoblastic Leukemia | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Refractory Adult Acute Lymphoblastic Leukemia | Refractory Diffuse... and other conditions

United States
Novartis Pharmaceuticals

Active, not recruiting

Tisagenlecleucel in Adult Patients With Aggressive B-cell Non-Hodgkin Lymphoma (BELINDA)

Non-Hodgkin Lymphoma

Spain, Taiwan, Australia, Belgium, Germany, Italy, Singapore, Austria, France, Switzerland, Hong Kong, United States, Netherlands, Norway, United Kingdom, Brazil, China, Japan
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic Leukemia

Recurrent Adult Burkitt Lymphoma | Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Recurrent Small Lymphocytic Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Post-Transplant Lymphoproliferative Disorder | Recurrent Chronic Lymphocytic Leukemia | Recurrent Follicular Lymphoma and other conditions

United States
Juno Therapeutics, a Subsidiary of Celgene
Bristol-Myers Squibb

Completed

A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting (TRANSCEND-OUTREACH-007)

Neoplasms | Neoplasms by Histologic Type | Lymphoma | Lymphoma, B-Cell | Lymphoma, Large B-Cell, Diffuse | Lymphoproliferative Disorders | Lymphatic Diseases | Immunoproliferative Disorders | Lymphoma, Non-Hodgkin | Immune System Disorder

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI); AstraZeneca; Juno Therapeutics, Inc.; MedImmune...

Terminated

JCAR014 and Durvalumab in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Recurrent Diffuse Large B-Cell Lymphoma | Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements | Diffuse Large B-Cell Lymphoma, Not Otherwise Specified

United States
Molecular Templates, Inc.

Terminated

Safety, PD & Efficacy of MT-3724 for the Treatment of Patients With Relapsed or Refractory DLBCL (MT-3724NHL001)

Leukemia, Lymphocytic, Chronic, B-Cell | Diffuse Large B Cell Lymphoma | Blood Cancer | Hematological Malignancy | Small Lymphocytic Leukemia | Non-Hodgkin's B-cell Lymphoma

United States, Canada, Georgia, Belarus, Spain, Israel, Moldova, Republic of, Poland, Serbia, Ukraine
Adicet Bio, Inc

Enrolling by invitation

Long-term Follow-up Study of Allogeneic Gamma Delta (γδ) CAR T Cells

Lymphoma, Follicular | Lymphoma, Non-Hodgkin | Lymphoma, Mantle-Cell | Marginal Zone Lymphoma | Diffuse Large B Cell Lymphoma | Primary Mediastinal B-cell Lymphoma

United States
National Cancer Institute (NCI)

Completed

CAR T Cell Receptor Immunotherapy for Patients With B-cell Lymphoma

Primary Mediastinal B-cell Lymphoma | Diffuse, Large B-cell Lymphoma | Diffuse Large B-Cell Lymphoma Transformed From Follicular Lymphoma | Mantle Cell

United States
Second Affiliated Hospital of Xi'an Jiaotong University
Nanjing Legend Biotech Co.

Terminated

A Single-center Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of LCAR-L10D Cell Formulations Targeting CD19 and CD22 in Patients With CD19- and/or CD22-Positive Relapsed/Refractory B-cell Lymphoma

Lymphoma, B-Cell

China
Ahmed Galal, MD

Withdrawn

Microtransplantation and Checkpoint Blockade Immunotherapy for Relapsed or Refractory B Cell Lymphomas (MicroBLITZ)

B Cell Lymphomas

United States
Altor BioScience

Terminated

QUILT-3.002: ALT-803 in Patients With Relapse/Refractory iNHL in Conjunction With Rituximab

Relapsed/Refractory Indolent B Cell Non-Hodgkin Lymphoma

United States
UCB Pharma

Completed

Study of Epratuzumab Versus Placebo in Subjects With Moderate to Severe General Systemic Lupus Erythematosus (SLE) (EMBODY2)

Systemic Lupus Erythematosus

United States, Brazil, Canada, France, Germany, Hungary, India, Italy, Mexico, Poland, Romania, Russian Federation, South Africa, Spain, Ukraine, United Kingdom
National Cancer Institute (NCI)

Completed

Anti-CD19 White Blood Cells for Children and Young Adults With B Cell Leukemia or Lymphoma

Leukemia | B Cell Lymphoma | Non-Hodgkin Lymphoma | ALL | Large Cell Lymphoma

United States
Hebei Yanda Ludaopei Hospital
Gracell Biotechnology Ltd.

Unknown

A Study of GC022F CAR-T Cell Immunotherapy for Relapsed or Refractory B- NHL

B-cell Non Hodgkin Lymphoma

China
Chinese PLA General Hospital

Unknown

Safety and Efficiency Study of CD19-PD1-CART Cell in Relapsed/Refractory B Cell Lymphoma

Lymphoma, B-Cell

China
Molecular Templates, Inc.

No longer available

Extended Treatment Access Study of MT-3724 for Subjects With Relapsed Non-Hodgkin's B-Cell Lymphoma

Non-Hodgkin's B-cell Lymphoma

United States
Institute of Hematology & Blood Diseases Hospital
Cancer Institute and Hospital, Chinese Academy of Medical Sciences; Beijing...

Unknown

γδT Cells Immunotherapy in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL)

Non-Hodgkin's Lymphoma | Peripheral T Cell Lymphoma | Relapsed or Refractory B Cell Non-Hodgkin's Lymphoma | Chronic Lymphoblastic Leukemia

China
Fuda Cancer Hospital, Guangzhou
Shenzhen Hank Bioengineering Institute

Completed

Combination of Rituximab and NK Immunotherapy for B Lymphoma

B-cell Lymphoma Recurrent

China
M.D. Anderson Cancer Center
Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma

Completed

Immunotherapy With NK Cell, Rituximab and Rhu-GMCSF in Non-Myeloablative Allogeneic Stem Cell Transplantation

Lymphoma | Leukemia | Lymphoid Malignancies | Disorder Related to Transplantation | Transplantation, Stem Cell

United States
Ruijin Hospital

Unknown

Lenalidomide Based Immunotherapy in the Treatment of DLBCL

Diffuse Large B Cell Lymphoma

China
Seagen Inc.

Terminated

Denintuzumab Mafodotin (SGN-CD19A) Combined With RCHOP or RCHP Versus RCHOP Alone in Diffuse Large B-Cell Lymphoma or Follicular Lymphoma

Diffuse, Large B-Cell, Lymphoma | Follicular Lymphoma, Grade 3b | Transformed Lymphoma / DLBCL

United States, Puerto Rico
MedImmune LLC

Completed

MEDI4736 Alone and in Combination With Tremelimumab or AZD9150 in Adult Subjects With Relapsed/Refractory DLBCL (D4190C00023)

Diffuse Large B-Cell Lymphoma

United States, France, United Kingdom, Ireland
UCB Pharma

Completed

Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus (EMBODY4)

Systemic Lupus Erythematosus

United States, Brazil, Canada, France, Germany, Hungary, Italy, Mexico, Poland, Romania, Russian Federation, South Africa, Spain, Ukraine, United Kingdom, Australia, Belgium, Bulgaria, Czechia, Estonia, Israel, Korea, Republic of, T... and more
UCB Pharma

Completed

Study of Epratuzumab Versus Placebo in Subjects With Moderate to Severe General Systemic Lupus Erythematosus (EMBODY1)

Systemic Lupus Erythematosus

United States, Australia, Belgium, Brazil, Bulgaria, Czechia, Estonia, France, Germany, India, Israel, Italy, Korea, Republic of, Lithuania, Mexico, Puerto Rico, Romania, Russian Federation, Spain, Taiwan, United Kingdom
National Cancer Institute (NCI)

Completed

Adoptive Cell Therapy for B-Cell Cancers in Patients After Stem Cell Transplantation

Chronic Lymphocytic Leukemia

United States
Gesellschaft fur Medizinische Innovation - Hamatologie...
Celgene; Amgen

Terminated

Therapy of Non-Hodgkin-Lymphoma by Combination of Lenalidomide + Rituximab, Dexa, High-dose ARA-C and CisP (R²-DHAP)

Diffuse Large B-cell Lymphoma (DLBCL) | Burkitt Lymphoma (BL) | Follicular Lymphoma Grade III (FL III°) | Mantle Cell Lymphoma (MCL), Blastoid Variant | Aggressive Marginal Zone Lymphoma (MZL)

Germany
Chinese PLA General Hospital

Unknown

A Feasibility and Safety Study of Universal Dual Specificity CD19 and CD20 or CD22 CAR-T Cell Immunotherapy for Relapsed or Refractory Leukemia and Lymphoma

B Cell Lymphoma | B Cell Leukemia

China
National Cancer Institute (NCI)

Completed

Active Specific Immunotherapy for Follicular Lymphomas With Tumor-Derived Immunoglobulin Idiotype Antigen Vaccines

Lymphoma | Follicular Lymphoma | B Cell Lymphoma

United States
Chinese PLA General Hospital

Unknown

A Study Evaluating UCART019 in Patients With Relapsed or Refractory CD19+ Leukemia and Lymphoma

B Cell Lymphoma | B Cell Leukemia

China
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
The First People's Hospital of Hefei; Hefei Binhu Hospital

Unknown

PCAR-119 Bridge Immunotherapy Prior to Stem Cell Transplant in Treating Patients With CD19 Positive Leukemia and Lymphoma

Follicular Lymphoma | Mantle Cell Lymphoma | Chronic Lymphocytic Leukemia | Acute Lymphocytic Leukemia | Diffuse Large Cell Lymphoma | B-cell Prolymphocytic Leukemia

China
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Anhui Provincial Hospital; The First People's Hospital of Hefei; Hefei Binhu...

Unknown

CAR-T Cell Immunotherapy in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma

Follicular Lymphoma | Mantle Cell Lymphoma | Chronic Lymphocytic Leukemia | Acute Lymphocytic Leukemia | Diffuse Large Cell Lymphoma | B-cell Prolymphocytic Leukemia

China
University of North Carolina, Chapel Hill

Withdrawn

Walnut Oral Immunotherapy for Tree Nut Allergy (WOIT)

Nut Hypersensitivities
Jichi Medical University
Takara Bio Inc.

Unknown

Gene Therapy for B-Cell Non-Hodgkin Lymphoma Using CD19 CAR Gene Transduced T Lymphocytes

Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Japan
Merck KGaA, Darmstadt, Germany

Completed

EMD 521873 in Advanced Solid Tumors, MTD Finding

Non-Hodgkin Lymphoma

Germany, Switzerland
UCB Pharma

Withdrawn

Study of Epratuzumab in Systemic Lupus Erythematosus

Systemic Lupus Erythematosus

United States, France, United Kingdom, Spain, Belgium, Netherlands, Canada, Brazil, Germany, Hungary, Czech Republic, Italy, Slovakia
UCB Pharma

Completed

Study of Epratuzumab in Systemic Lupus Erythematosus

Systemic Lupus Erythematosus

United States
UCB Pharma

Completed

Open-label Study of Epratuzumab in Serologically-positive Systemic Lupus Erythematosus Patients With Active Disease

Systemic Lupus Erythematosus

United States, Poland, Spain, Belgium, India, Ukraine, Brazil, United Kingdom, Hungary, Lithuania, Hong Kong
UCB Pharma

Completed

Study of Epratuzumab in Serologically-positive Systemic Lupus Erythematosus (SLE) Patients With Active Disease

Systemic Lupus Erythematosus

United States, Poland, Spain, Belgium, India, Ukraine, Brazil, United Kingdom, Hungary, Lithuania, Hong Kong

Search clinical trials for: B-Cell Immunotherapy

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Iran

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations